Applied Genetic Technologies Corporation (AGTC)
(Delayed Data from NSDQ)
$4.30 USD
-0.04 (-0.92%)
Updated May 3, 2019 04:13 PM ET
After-Market: $4.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.30 USD
-0.04 (-0.92%)
Updated May 3, 2019 04:13 PM ET
After-Market: $4.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Applied Genetic Technologies (AGTC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -17.65% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Applied Genetic Technologies (AGTC) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Applied Genetic Technologies (AGTC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Applied Genetic Technologies (AGTC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AGTC) Outperforming Other Medical Stocks This Year?
Zealand Announces Dosing Initiation in Type 2 Diabetes Study
by Zacks Equity Research
Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.
Applied Genetic (AGTC) Soars: Stock Adds 6.1% in Session
by Zacks Equity Research
Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Dynavax's Partner Doses First Patient in Coronavirus Study
by Zacks Equity Research
Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.
Reata Surges on $350 Million Investment Deal With Blackstone
by Zacks Equity Research
Reata (RETA) announces a royalty and equity investment deal with Blackstone Group, which will support development of its lead pipeline candidate, bardoxolone methyl, in chronic kidney diseases.
Is Applied Genetic Technologies (AGTC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AGTC) Outperforming Other Medical Stocks This Year?
Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B
by Zacks Equity Research
Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.
Mersana Stock Spikes on Interim Data on Cancer Candidate
by Zacks Equity Research
Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
Why Applied Genetic Technologies (AGTC) Stock Might be a Great Pick
by Zacks Equity Research
The Applied Genetic Technologies (AGTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Applied Genetic Technologies (AGTC) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Applied Genetic Technologies (AGTC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGTC) Outperforming Other Medical Stocks This Year?
Applied Genetic Technologies (AGTC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 9.09% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Applied Genetic Technologies' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Applied Genetic Technologies.
Earnings Preview: Applied Genetic Technologies (AGTC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Applied Genetic Technologies' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Applied Genetic Technologies.
All You Need to Know About Applied Genetic Technologies (AGTC) Rating Upgrade to Buy
by Zacks Equity Research
Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied Genetic Stock Up on Favorable Eye Therapy Study Data
by Zacks Equity Research
Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
Company News for Jan 10, 2020
by Zacks Equity Research
Companies In The News Are:
Implied Volatility Surging for Applied Genetic Technologies (AGTC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -10.34% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Applied Genetic Technologies (AGTC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?